Actively Recruiting
Tamoxifen Versus Etoposide After First Recurrence in GBM Patients
Led by AHS Cancer Control Alberta · Updated on 2025-06-26
60
Participants Needed
1
Research Sites
282 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The investigator propose a single-center randomized phase II controlled study designed to compare the management of first recurrence of GBM using etoposide versus tamoxifen.
CONDITIONS
Official Title
Tamoxifen Versus Etoposide After First Recurrence in GBM Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed glioblastoma multiforme with progression after initial chemoradiotherapy with temozolomide
- Progression shown by MRI with at least one measurable lesion of 10 mm or larger visible on two or more axial slices
- No radiotherapy received within 3 months before progression diagnosis
- Stable or decreasing corticosteroid dose before randomization to control brain swelling symptoms
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Age between 18 and 65 years
- Women of childbearing potential must have a negative pregnancy test within 72 hours before treatment
- Patients of reproductive potential must use effective birth control during treatment and for 60 days after last dose
- Laboratory tests within 7 days before randomization showing adequate blood counts and organ function
- Patient understands and signs informed consent prior to registration
You will not qualify if you...
- History of another cancer or concurrent cancer, except if disease-free for 3 years or certain treated skin or in situ cancers
- Uncontrolled high blood pressure (systolic >150 mm Hg or diastolic >100 mm Hg)
- Any arterial or venous thrombosis within 6 months before registration
- Recent brain hemorrhage seen on MRI
- Significant heart or vascular disease including recent stroke or heart attack within 6 months, unstable angina, congestive heart failure above Class II, or serious arrhythmia requiring medication
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cross Cancer Institute
Edmonton, Alberta, Canada
Actively Recruiting
Research Team
J
Jacob Easaw, MD, PhD, FRCPC
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here